INOVIQ's recent validation study of its EXO-OC test revealed it can detect stage one ovarian cancer with 96% specificity and more than 90% sensitivity, a promising advance for early detection.
The company's breast cancer screen test has also demonstrated superior accuracy over current tests.
Copyright 2024 – Finance News Network
Source: Finance News Network
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More01 Dec 2021 - MinRex Resources Limited (ASX:MRR) Non-Executive Director George Karageorge provides an update on the company's gold and base metals projects in WA and the Lachlan Ford Belt, NSW and its recently acquired lithium projects in the Pilbara.
Read More21 Oct 2019 - PPK Group Limited (ASX:PPK) Executive Chairman, Robin Levinson talks about FY19 results, strategy, pickup in the company's key market, and the company's joint venture with Deakin University for Boron Nitrate Nanotubes.
Read More09 Jun 2022 - Novatti Group Limited (ASX:NOV) CEO and Managing Director Peter Cook discusses Novatti's recent deals with Ripple and Stellar.
Read More26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More16 Aug 2023 - Yoav Amitai - CEO - Elsight's (ASX:ELS) Halo provides connectivity and delivers absolute connection confidence for drones and other unmanned systems.
Read More29 Mar 2021 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt talks about the Bristol Myers Squibb trial evaluating Anti-LAG-3 Antibody Relatlimab and Opdivo (nivolumab) in patients with previously untreated metastatic or unresectable melanoma, meeting its primary endpoint of progression-free survival and what it means for Immutep.
Read More01 May 2020 - Acorn Capital, Head of Portfolio Implementation and Portfolio manager (Healthcare and Biotechnology sectors) Paul Palumbo looks the microcap sector and the recent market sell off and discusses the outlook for next 6 months and longer term.
Read More29 Mar 2021 - Telix Pharmaceuticals Limited (ASX:TLX) Chief Business Officer Dr David Cade talks about the company's clinical programs, including approvals, partnerships and significant value events anticipated in 2021.
Read More16 May 2023 - ABx Group Limited (ASX:ABX) CEO and Managing Director Dr Mark Cooksey discusses the advantages of ionic clay rare earths deposits, the company's exploration program, its plays for a scoping study and a pilot plant, and its new process to develop fluorine from aluminium smelting waste.
Read More
